Patents by Inventor Satoshi UMEZAKI

Satoshi UMEZAKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11465965
    Abstract: The present invention provides a compound that is highly safe and useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical composition containing the compound, a method for producing the compound, and the like. Specifically, the present invention provides a compound represented by the following general formula (I): [wherein: A1 and A2 each independently represent an inhibitor residue having at least one activity selected from an enteropeptidase inhibitory activity and a trypsin inhibitory activity; and Z represents a spacer that links A1 to A2] or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: October 11, 2022
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Haruka Yamada, Ken-ichi Komori, Yusuke Shiraishi, Satoshi Umezaki, Naoya Kinoshita, Koji Ito, Tomoko Kanda, Kenji Yoneda, Yasunori Tokunaga, Tomio Kimura
  • Patent number: 10968238
    Abstract: Methods of producing a compound represented by formula (I) or a pharmacologically acceptable salt thereof include: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: April 6, 2021
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Noriaki Iwase, Shigeyuki Kono, Masayuki Tanaka, Masaaki Matoyama, Satoshi Umezaki, Yusuke Shiraishi, Masahiro Kojima, Hayato Nishiyama
  • Patent number: 10894798
    Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: January 19, 2021
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Noriaki Iwase, Yasuhiro Aga, Shigeru Ushiyama, Shigeyuki Kono, Hidetoshi Sunamoto, Takashi Matsushita, Sayaka Ogi, Satoshi Umezaki, Masahiro Kojima, Kazuhiro Onuma, Yusuke Shiraishi, Makoto Okudo, Tomio Kimura
  • Publication number: 20200347011
    Abstract: The present invention provides a compound that is highly safe and useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical composition containing the compound, a method for producing the compound, and the like. Specifically, the present invention provides a compound represented by the following general formula (I): [wherein: A1 and A2 each independently represent an inhibitor residue having at least one activity selected from an enteropeptidase inhibitory activity and a trypsin inhibitory activity; and Z represents a spacer that links A1 to A2] or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 2, 2018
    Publication date: November 5, 2020
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Haruka YAMADA, Ken-ichi KOMORI, Yusuke SHIRAISHI, Satoshi UMEZAKI, Naoya KINOSHITA, Koji ITO, Tomoko KANDA, Kenji YONEDA, Yasunori TOKUNAGA, Tomio KIMURA
  • Publication number: 20190256531
    Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.
    Type: Application
    Filed: April 3, 2019
    Publication date: August 22, 2019
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Noriaki IWASE, Yasuhiro AGA, Shigeru USHIYAMA, Shigeyuki KONO, Hidetoshi SUNAMOTO, Takashi MATSUSHITA, Sayaka OGI, Satoshi UMEZAKI, Masahiro KOJIMA, Kazuhiro ONUMA, Yusuke SHIRAISHI, Makoto OKUDO, Tomio KIMURA
  • Patent number: 10273252
    Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: April 30, 2019
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Noriaki Iwase, Yasuhiro Aga, Shigeru Ushiyama, Shigeyuki Kono, Hidetoshi Sunamoto, Takashi Matsushita, Sayaka Ogi, Satoshi Umezaki, Masahiro Kojima, Kazuhiro Onuma, Yusuke Shiraishi, Makoto Okudo, Tomio Kimura
  • Publication number: 20190062353
    Abstract: Methods of producing a compound represented by formula (I) or a pharmacologically acceptable salt thereof include: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.
    Type: Application
    Filed: October 30, 2018
    Publication date: February 28, 2019
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Noriaki IWASE, Shigeyuki KONO, Masayuki TANAKA, Masaaki MATOYAMA, Satoshi UMEZAKI, Yusuke SHIRAISHI, Masahiro KOJIMA, Hayato NISHIYAMA
  • Patent number: 10131679
    Abstract: Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 20, 2018
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Yasuhiro Aga, Shigeru Ushiyama, Noriaki Iwase, Shigeyuki Kono, Hidetoshi Sunamoto, Takashi Matsushita, Sayaka Ogi, Masayuki Tanaka, Masaaki Matoyama, Satoshi Umezaki, Yusuke Shiraishi, Kazuhiro Onuma, Masahiro Kojima, Hayato Nishiyama, Tomio Kimura
  • Publication number: 20180186818
    Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.
    Type: Application
    Filed: June 14, 2016
    Publication date: July 5, 2018
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Noriaki IWASE, Yasuhiro AGA, Shigeru USHIYAMA, Shigeyuki KONO, Hidetoshi SUNAMOTO, Takashi MATSUSHITA, Sayaka OGI, Satoshi UMEZAKI, Masahiro KOJIMA, Kazuhiro ONUMA, Yusuke SHIRAISHI, Makoto OKUDO, Tomio KIMURA
  • Publication number: 20170313727
    Abstract: Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.
    Type: Application
    Filed: October 30, 2015
    Publication date: November 2, 2017
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Yasuhiro AGA, Shigeru USHIYAMA, Noriaki IWASE, Shigeyuki KONO, Hidetoshi SUNAMOTO, Takashi MATSUSHITA, Sayaka OGI, Masayuki TANAKA, Masaaki MATOYAMA, Satoshi UMEZAKI, Yusuke SHIRAISHI, Kazuhiro ONUMA, Masahiro KOJIMA, Hayato NISHIYAMA, Tomio KIMURA